Discontinued — last reported Q4 '22

Other Working Capital

Operating

Eli Lilly Other Working Capital decreased by 100.0% to $0.00 in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $542.80M to $0.00. Over 4 years (FY 2021 to FY 2025), Other Working Capital shows an upward trend with a 7.4% CAGR.

Analysis

StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ1 2015
Last reportedQ4 2022

How to read this metric

Positive changes suggest a source of cash from optimizing minor balance sheet items, while negative changes indicate cash is being tied up in these categories.

Detailed definition

The aggregate net change in miscellaneous operating assets and liabilities not specifically categorized in major line it...

Peer comparison

This is often used to reconcile net income to cash flow and varies based on a company's specific accounting classifications for 'other' items.

Metric ID: cf_change_in_other_working_capital

Historical Data

19 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Value$188.50M$185.10M$6.70M$32.60M-$81.80M$266.80M$87.20M$168.30M-$550.70M$485.60M$192.30M$298.60M-$31.90M-$32.10M$542.80M$324.80M$54.40M$302.30M$0.00
QoQ Change-1.8%-96.4%+386.6%-350.9%+426.2%-67.3%+93.0%-427.2%+188.2%-60.4%+55.3%-110.7%-0.6%>999%-40.2%-83.3%+455.7%-100.0%
YoY Change-143.4%+44.1%>999%+416.3%-573.2%+82.0%+120.5%+77.4%+94.2%-106.6%+182.3%+8.8%+270.5%>999%-100.0%
Range-$550.70M$542.80M
CAGR-100.0%
Avg YoY Growth+174.4%
Median YoY Growth+82.0%

Frequently Asked Questions

What is Eli Lilly's other working capital?
Eli Lilly (LLY) reported other working capital of $0.00 in Q4 2025.
How has Eli Lilly's other working capital changed year-over-year?
Eli Lilly's other working capital decreased by 100.0% year-over-year, from $542.80M to $0.00.
What is the long-term trend for Eli Lilly's other working capital?
Over 4 years (2021 to 2025), Eli Lilly's other working capital has grown at a 7.4% compound annual growth rate (CAGR), from $511.40M to $681.50M.
What does other working capital mean?
The cash impact from changes in various smaller business assets and obligations used in daily operations.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.